Persistence of Immune Response After Vaccination With MCC

Phase 4

Completed

• Conditions: Prevention of Meningococcal Infection

• Registration Number: NCT00310687
• Lead Sponsor: Novartis

Brief Summary

Persistence of Immune response after vaccination with MCC

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2004-10
• Primary Completion: 2005-12
• Study Completion: 2005-12
• Study First Submitted: 2006-04-03
• Study First Submitted QC: 2006-04-03
• Study First Posted: 2006-04-04
• Status Verified: 2014-09
• Last Update Submitted: 2014-09-18
• Last Update Posted: 2014-09-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1244

Inclusion Criteria

• healthy adolescents vaccinated with Meningococcal C Conjugate vaccine

Read More

Exclusion Criteria

• ascertained or suspected disease caused by N. meningitidis
• household contact with individuals with proven N. meningitidis serogroup C infection
• significant acute or chronic infections
• any other serious disease

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
persistence of memory response to N. meningitidis serogroup C as measured by serum bactericidal activity at one year after either a challenge with 1/5 of a dose of Meningococcal A/C Polysaccharide vaccine or a booster dose of MenC Vaccine.

Secondary Outcome Measures

Name	Time	Method
Evaluation of the immunological response (ELISA) to N. meningitidis serogroup C
Evaluation and comparison of the persistence of antibodies against N. meningitidis serogroup C as measured by hBCA

Trial Locations

Locations (1)

Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital; 🇬🇧 Headington, Oxfordshire, United Kingdom